Stock Price Quote

SYNCOM HEALTHCARE LTD.

NSE : SYNCOMBSE : 533157ISIN CODE : INE602K01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE4.120 (0 %)
PREV CLOSE ( ) 4.12
OPEN PRICE ( ) 3.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 163615
TODAY'S LOW / HIGH ( )3.95 4.33
52 WK LOW / HIGH ( )3.95 4.33
NSE4.200 (0 %)
PREV CLOSE( ) 4.20
OPEN PRICE ( ) 4.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 4.20 (50)
VOLUME 332739
TODAY'S LOW / HIGH( ) 3.95 4.30
52 WK LOW / HIGH ( )3.95 4.3
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 29-07 2002
Management Info
- Chairman Ajay Shankarlal Bankda - Managing Director
Registered Office

Address Shop No. F-44, 1st Floor Shagun Arcade,Co-operative Society Ltd., A K Vaidya Marg,,Opp. Hdfc Bank, Malad East,
Mumbai,
Maharashtra-400097

Phone

Email shl@syncomhealthcare.com

Website www.syncomhealthcare.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

05Jul Syncom Healthcare informs about disclo
In terms of Regulation 23(9) of SEBI (Listing Obligations and Disclosure..
10Jul Syncom Healthcare informs about disclo
Syncom Healthcare has informed that the exchange has received the disclo..
06Sep Syncom Healthcare informs about annua
Syncom Healthcare has informed that it has enclosed the Annual Report of..
18Jun Syncom Healthcare informs about outcom
Syncom Healthcare has informed about outcome of board meeting held on 17..
05Apr Syncom Healthcare informs about closur
Syncom Healthcare has informed about closure of trading window of the co..

Financials

in Millions
QTR Jun 21 ANNUAL 21
Net Profit-11.06-49.09
Gross Profit -11.06 -49.09
Operating Profit -7.23-28.95
Net Sales 3.5218.32

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Procter&Gamble Healt (BSE)
peergroup  4800.00 (2.12%)
M.Cap ( in Cr)7846.94
Mankind Pharma (BSE)
peergroup  2401.15 (2.71%)
M.Cap ( in Cr)96311.48
Torrent Pharma (BSE)
peergroup  2642.50 (2.00%)
M.Cap ( in Cr)88554.25
Astrazeneca Pharma I (BSE)
peergroup  5258.60 (0.78%)
M.Cap ( in Cr)13099.50
Concord Biotech (BSE)
peergroup  1620.00 (2.41%)
M.Cap ( in Cr)17096.38

Shareholding Pattern

NON-INSTITUTION 99.87%
PROMOTERS 0.13%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Syncom Healthcare Ltd.

Syncom Healthcare Ltd. was incorporated in the year 2002. Its today's share price is 4.12. Its current market capitalisation stands at Rs 16.48 Cr. In the latest quarter, company has reported Gross Sales of Rs. 199.67 Cr and Total Income of Rs.202.27 Cr. The company's management includes Farida Bhatia, Bhismapal Singh Yadav, Sunita Garg, Tushar Patodia, Manoj Negi, Ajay Shankarlal Bankda.

It is listed on the BSE with a BSE Code of 533157 , NSE with an NSE Symbol of SYNCOM and ISIN of INE602K01014. It's Registered office is at Shop No. F-44, 1st Floor Shagun Arcade,Co-operative Society Ltd., A K Vaidya Marg,,Opp. Hdfc Bank, Malad EastMumbai-400097, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Bhatter & Co, Karnavat & Co, Sanjay Mehta & Associates, SG Kabra & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.